+ Watch CBM
on My Watchlist
A life sciences company provides products and services that accelerate and improve the discovery and commercialization of human therapeutics.
Re-upping to get back in before earnings. I think after people realize that the remaining company is not worth $12/share, the stock will tank.Does anybody have mulitple information for the remaining piece of the company? Does $12/share = a PE of 10, 20, 50?
How about CBM's Q2 earnings? $0.08/share. Sales were flat, until you take out the forex benefit - which takes it to -3.5%. Plus, they are reporting that Q3 will be "soft" and they "think" that Q4 will be stronger, but they don't know how product mix and customer progress will affect their earnings. Who's the captain of this ship? Do they really know what's happening with their business?$12/share at a PE of 20 would require $0.60/share of earning. Will they have that kind of earnings potential going forward? Doubt it.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions